Simultaneous Determination of Telmisartan and Pitavastatin Calcium in Intestinal Perfusate by HPLC: Application to Intestinal Absorption Interaction Study.

Pharmaceutical Nanotechnology
Junying WangChunmei Fu

Abstract

Hypertension and hypercholesterolemia are two main physiological risk factors of cardiovascular disease, and commonly occur in combination. Multicompound combination therapy is rational for the treatment of concurrent hypertension and hypercholesterolemia, while telmisartan and pitavastatin calcium can be used as a potential drug combination. The aim of this paper is to study the intestinal absorption and absorption interaction of telmisartan and pitavastatin calcium. An HPLC method was developed and validated to determine telmisartan and pitavastatin calcium in intestinal perfusate simultaneously. The in situ single-pass perfusion in rats was utilized to investigate the effects of concentrations, intestinal segment (duodenum, jejunum, ileum and colon) and co-administrated drugs on absorption. The effective permeability coefficient and the absorption rate constant of telmisartan were higher in the duodenum as compared to other intestinal segments. However, the intestinal absorption of pitavastatin calcium was not segmental dependent. The effective permeability coefficient and absorption rate constant have no significant difference among three concentrations of telmisartan, pitavastatin calcium individually and their combination...Continue Reading

References

Sep 1, 1996·Pharmaceutical Research·U FagerholmH Lennernäs
Mar 19, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Debbie TamK Sandy Pang
Jun 28, 2003·BMJ : British Medical Journal·N J Wald, M R Law
Nov 26, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Arik DahanGordon L Amidon
Feb 12, 2010·The Journal of International Medical Research·M Burnier
May 8, 2010·Vascular Health and Risk Management·Domenico GalzeranoCarlo Gaudio
Jan 5, 2011·Atherosclerosis. Supplements·John Betteridge
Mar 31, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Marques da Silva
Mar 29, 2014·European Journal of Preventive Cardiology·Anushka PatelUNKNOWN Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration
Apr 23, 2014·Annals of Global Health·Brandon Wiley, Valentin Fuster
Jan 1, 2012·The Cochrane Database of Systematic Reviews·Angharad N de CatesMark Huffman
Sep 27, 2015·Circulation·Gregory A RothChristopher J L Murray
Jun 4, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michel E BertrandJean-Jacques Mourad

❮ Previous
Next ❯

Citations

Oct 13, 2020·Pharmaceutical Nanotechnology·Yu Nie, Xiangrong Song

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.